6634.TWO

Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.